Brainstorm Cell Therapeutics Investor Presentation — March 2018

Document content

February 11, 2019 בס"ד

Forward Looking Statement

Statements in this announcement other than historical data and information constitute "forward -looking statements" and involve r isks and

uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or impl ied by such forward -

looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan ", "estimate", "predict",

"potential", and similar terms and phrases are intended to identify these forward -looking statements. The potential risks and u ncertainties include,

without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license

to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consu ltants; ability to obtain

required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10 -K and quarterly reports on Fo rm 10 -Q available

at http://www.sec.gov .

These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward -looking statem ents. The forward -

looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of th e date of this press

release. We do not assume any obligation to update forward -looking statements to reflect actual results or assumptions if circum stances or

management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations

reflected in the forward -looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Brainstorm at a Glance

Clinical stage biotechnology company developing innovative autologous cellular

therapies for neurodegenerative disease

Actively recruiting phase 3 clinical trial in ALS, an orphan disease with no

existing cure and limited treatment options

Large addressable markets – progressive MS (500K US) and ALS (30K US)

Proven technology platform and strong manufacturing capabilities בס"ד

7 Days Differentiation Expansion

Transplantation Harvesting

Expansion Isolation 1

3 Manufacturing process begins with a

bone marrow aspiration to harvest

adult MSCs from the patient

The proprietary culture medium

induces the cells to secrete additional